Head-to-head · WeighScore
Eden vs Henry Meds
By GLP-1 ScorecardUpdated
Score comparison
Eden has the higher recorded score — 81.6/100 to 77.3/100.
Eden grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
Before you choose
Before comparing the headline prices, the Eden review and the Henry Meds review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Eden vs Hims and Edessa vs Henry Meds compare each of them with another graded program, and the list of alternatives to Eden ranks the programs closest to Eden on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Eden | Henry Meds |
|---|---|---|
| WeighScore | 81.6/100 | 77.3/100 |
| Grade | B− | C+ |
| Site position | #16 | #47 |
| Semaglutide | Advertised $99/mo bundle; linked membership terms conflict—confirm checkout | $197/mo (injectable; 12-month plan paid upfront in full, $2,364) |
| Tirzepatide | Advertised $129/mo bundle; linked membership terms conflict—confirm checkout | Oral compounded plans; confirm selected price and supply |
| Coverage | All 50 states | Multi-state |
| Brand-name access | Yes | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Site position #16 · B−
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Strengths
- Current compounded offer includes medication and support
- Homepage also advertises branded prescription pathways; eligibility and cost require confirmation
- Named pharmacy operation and partner network can be investigated
What to consider
- Linked membership terms describe a separate fee model
- Landing-page warranty and terms use different thresholds and conditions
- FDA warning history remains relevant; a new offer does not establish resolution
Site position #47 · C+
Strengths
- Published plan prices identify their upfront-payment requirement
- Medication, provider access, applicable supplies and shipping included if prescribed
- Compounded injectable semaglutide and oral options listed
What to consider
- The $197 semaglutide headline requires $2,364 upfront, not monthly payments
- Oral program headings and supply descriptions conflict; obtain the selected written quote
- Multi-month balances may remain payable after cancellation; medical-discontinuation refunds require documentation and approval, and dispensed medication is excluded
Featured provider
Eden
Eden scores 81.6/100 (B−). Eden advertises lower-priced compounded bundles, but its offer and linked membership and warranty terms need to be reconciled before purchase.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Eden Health International Inc. dba Eden in June 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.